CD19/CD20 bicistronic CAR-T cell therapy (Kite Pharma)

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameCD19/CD20 bicistronic CAR-T cell therapy (Kite Pharma)
Drug Alias NameKITE-363
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-CD20
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKite Pharma
China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicLupus Nephritis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A